Propanc Biopharma, an Australia-based biotech company, has announced a significant and “transformative” move by securing up to $100 million from crypto-focused family office, Hexstone Capital. This substantial private placement is set to fund the creation of a digital asset treasury and accelerate the development of Propanc’s lead cancer therapy, PRP, which is slated to enter human trials in the second half of 2026.
The deal, structured through convertible preferred stock, provides Propanc with an initial $1 million investment, with the potential for an additional $99 million over the next 12 months. Propanc CEO James Nathanielsz emphasized the strategic importance of this crypto treasury, stating it will strengthen the company’s balance sheet and advance its proenzyme-based oncology platform. Nathanielsz highlighted the broad potential of their therapy, aiming to target not only metastatic cancer from solid tumors but also various chronic diseases.
While the specific digital assets Propanc plans to acquire for its crypto treasury remain undisclosed, Hexstone Capital’s clients have a diverse investment portfolio spanning major cryptocurrencies like Bitcoin (BTC), Ether (ETH), Solana (SOL), and Injective (INJ), alongside other lesser-known digital assets.
The Emerging Trend of Biotech and Crypto
Propanc’s embrace of a crypto strategy places it among a growing number of biotech companies, including Sonnet BioTherapeutics and Sharps Technology, that are turning to digital assets to invigorate investor interest. This innovative approach reflects a broader trend of companies exploring alternative funding and treasury management strategies in the evolving financial landscape.
Investor Reaction and Market Performance
Despite the company’s optimistic outlook, Propanc’s announcement was met with a degree of skepticism from its investors. Shares of PPCB experienced a 10.5% dip on the Nasdaq following the news, according to Yahoo Finance data.
This cautious investor response comes amid a period where crypto treasury strategies have seen mixed performance. The allure of Bitcoin treasury holding companies has somewhat diminished in recent months as more players enter the space. Notably, MicroStrategy, a prominent corporate Bitcoin holder, has seen its market capitalization decline by over 43% since July. Similarly, Metaplanet, a strong performer on the Tokyo Stock Exchange earlier in the year, has experienced a significant drop of approximately 55% since late June. Some Bitcoin treasury companies have even found it necessary to offload portions of their BTC holdings to manage outstanding debt.
Propanc’s venture into the crypto world marks a bold step for a biotech firm on the cusp of human trials for a potentially life-changing cancer therapy. The success of this strategy will undoubtedly be watched closely by both the biotech and crypto communities as it navigates the complexities and opportunities of this unique intersection.
